A5082509731- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Breast Implant and Reconstruction
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Cancer Risks and Factors
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Prostate Cancer Treatment and Research
- Global Cancer Incidence and Screening
- PI3K/AKT/mTOR signaling in cancer
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- MRI in cancer diagnosis
NSABP Foundation
2015-2025
Cancer Clinic
2025
National Cancer Institute
2009-2025
National Center for Tumor Diseases
2025
Helios Hospital Berlin-Buch
2025
Orlando Health
2015-2024
University of Florida Health
2015-2024
UF Health Cancer Center
2015-2024
NRG Oncology
2015-2024
Florida Hospital Cancer Institute
2024
We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women surgically removed HER2-positive breast cancer.
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy a worse prognosis than those no cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent (DM1), maytansine derivative microtubule inhibitor, provides benefit in patients with metastatic that was previously treated HER2-targeted therapy.
National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) overall (OS) compared with AC postoperatively. B-27 the effect adding docetaxel (T) preoperative on tumor response rates, DFS, OS.Analyses were limited eligible patients. In B-18, 751 patients assigned receive AC, 742 postoperative AC. B-27, 784 followed by...
Purpose: The National Surgical Adjuvant Breast and Bowel Project Protocol B-27 was designed to determine the effect of adding docetaxel after four cycles preoperative doxorubicin cyclophosphamide (AC) on clinical pathological response rates disease-free overall survival women with operable breast cancer. Patients Methods: Women (N = 2,411) primary cancer were randomly assigned receive either AC followed by surgery (group I), or docetaxel, II), then III). Clinical pathologic tumor responses...
This study was designed to determine the effect of adding docetaxel (T) preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates disease-free survival (DFS) overall (OS).Women with operable (N = 2,411) were randomly assigned receive AC followed by surgery, T or surgery then T. Tamoxifen initiated concurrently chemotherapy. Median time for 2,404 patients follow-up 77.9 months.Addition did not significantly impact DFS OS. There trends toward improved addition The...
PURPOSE In 1993, findings from a National Surgical Adjuvant Breast and Bowel Project (NSABP) trial to evaluate the worth of radiation therapy after lumpectomy concluded that combination was more beneficial than alone for localized intraductal carcinoma-in-situ (DCIS). This report extends those findings. PATIENTS AND METHODS Women (N = 818) with DCIS were randomly assigned or plus (50 Gy). Tissue removed so resected specimen margins histologically tumor-free. Mean follow-up time 90 months...
Women with ductal carcinoma in situ have been treated both by lumpectomy and followed radiation therapy, but the benefit of combined therapy is uncertain. A group 818 women were randomly assigned to undergo or breast irradiation (50 Gy). Sufficient tissue was removed that margins resected specimens histologically tumor-free. The mean duration follow-up 43 months (range, 11 86). principal end point study event-free survival, as defined presence no new ipsilateral contralateral cancers,...
Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines.National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin cyclophosphamide (AC) followed by paclitaxel AC plus 52 weeks trastuzumab beginning concurrently patients node-positive, HER2-positive cancer. Initiation required normal post-AC left ventricular ejection...
Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses four large trials. Initial data combined analysis North Central Cancer Treatment Group (NCCTG) N9831 Intergroup trial and National Surgical Adjuvant Breast Bowel Project (NSABP) B-31 were reported 2005. Long-term follow-up results on disease-free survival (DFS) overall (OS) awaited.Patients with...
The primary aim of National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 was to determine whether four cycles adjuvant paclitaxel (PTX) after doxorubicin/cyclophosphamide (AC) will prolong disease-free survival (DFS) overall (OS) compared with AC alone in patients resected operable breast cancer histologically positive axillary nodes.Between August 1995 May 1998, 3,060 were randomly assigned (AC, 1,529; followed by PTX [AC --> PTX], 1,531). Patients > or = 50 years those younger...
PURPOSE This study was designed to evaluate the efficacy of leucovorin-modulated fluorouracil (5-FU) as adjuvant therapy for patients with Dukes' stage B and C colon cancer. PATIENTS AND METHODS Data are presented from 1,081 carcinoma entered into National Surgical Adjuvant Breast Bowel Project (NSABP) protocol C-03 between August 1987 April 1989. Patients were randomly assigned receive either lomustine (MeCCNU), vincristine, 5-FU (MOF), or (LV + 5-FU). The mean time on 47.6 months. RESULTS...
PURPOSE: This trial was prompted by uncertainty about the need for breast irradiation after lumpectomy in node-negative women with invasive cancers of ≤ 1 cm, speculation that tamoxifen (TAM) might be as or more effective than radiation therapy (XRT) reducing rate ipsilateral tumor recurrence (IBTR) such women, and thesis both modalities either alone. PATIENTS AND METHODS: After lumpectomy, 1,009 were randomly assigned to TAM (n = 336), XRT placebo 337). Rates IBTR, distant recurrence,...
The 21-gene OncotypeDX recurrence score (RS) assay quantifies the risk of distant in tamoxifen-treated patients with node-negative, estrogen receptor (ER)-positive breast cancer. We investigated association between RS and for locoregional (LRR) ER-positive cancer from two National Surgical Adjuvant Breast Bowel Project (NSABP) trials (NSABP B-14 B-20).RS was available 895 (from both trials), 355 placebo-treated B-14), 424 chemotherapy plus B-20). primary end point time to first LRR. Distant...
Purpose Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated chemotherapy. Patients Methods During conduct National Surgical Adjuvant Breast Bowel Project B-27, several participating surgeons attempted SNB before required axillary dissection 428 patients. All underwent lymphatic mapping an attempt to identify remove node. Lymphatic was performed...
PURPOSE: To compare the efficacy of leucovorin-modulated fluorouracil (FU+LV) with that and levamisole (FU+LEV) or combination FU+LV (FU+LV+LEV). PATIENTS AND METHODS: Between July 1989 December 1990, 2,151 patients Dukes' B (stage II) C III) carcinoma colon were entered onto National Surgical Adjuvant Breast Bowl Project protocol C-04. Patients randomly assigned to receive (weekly regimen), FU + LEV, FU+LV+LEV. The average time on study was 86 months. RESULTS: A pairwise comparison between...
Purpose Cardiac dysfunction (CD) is a recognized risk associated with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer, especially when treatment regimen includes anthracyclines. Given demonstrated efficacy trastuzumab, ongoing assessment cardiac safety and identification factors CD are important optimal patient care. Patients Methods In National Surgical Adjuvant Breast Bowel Project B-31, phase III trial, 1,830...